The Novartis Institutes for BioMedical Research is ending its early-stage anti-infectives research programs located in Emeryville, Calif. As a result, the company expects to lay off about 140 employees.
Regulus Therapeutics announced a corporate restructuring that included the termination of 60 percent of the company’s workforce, which caused a massive stock plummet.
Purdue Pharma, which sells the painkiller OxyContin, announced that the company laid off approximately 350 staffers.
Boston-based Intarcia Therapeutics undertook a restructuring that includes the termination of up to 60 employees and the closing of two programs.
Pernix Therapeutics is undergoing a reorganization that includes the termination of a number of sales representatives.
Allergan will cut 1,000 positions, about 5 percent of its workforce, as the company looks to cut costs.
Teva Pharmaceutical announced a comprehensive restructuring plan that includes the elimination of 25 percent of the company’s global workforce.
Depomed Inc. is looking to relocate its headquarters from the Bay Area after inking a deal with Collegium Pharmaceutical Inc.
Otonomy, which develops innovative therapeutics for diseases and disorders of the ear, is initiating more job cuts as well as planning to divest one of its assets.
Mylan reportedly let go between 200 and 300 people from its West Virginia operations.
Roche company Genentech indicated it is laying off 130 people at its facility in Vacaville, Calif. by the end of 2017. Amgen is reportedly eliminating about 200 R&D jobs, mostly in California, by the end of 2017.
California-based Bio-Rad is shuttering a research and development facility in the white-hot biotech hub of Cambridge, Mass.
Shiel Medial Laboratory will terminate 538 employees at a New Jersey facility following the company’s acquisition by Quest Diagnostics. The layoffs were announced one day after Quest’s acquisition was announced.
Following a failure to determine clear efficacy in its experimental combo ovarian cancer drug, Mateon ended the drug program and cut 60% of its employees.
Genocea Biosciences is pivoting a development strategy to focus on development of neoantigen cancer treatments and scrapping its Phase III-ready herpes drug.
Nestle plans to cut up to 450 jobs at a Galderma research and development center in southern France, the Swiss company said.
Otonomy is cutting jobs and slashing operations in order to stay in business.
Eli Lilly and Company announced the company plans to cut 3,500 jobs. The majority of the job cuts will be in the U.S., and include voluntary early retirement programs.
As Bristol-Myers Squibb’s HIV drugs Reyataz and Sustiva lose patent protection, the company plans to lay off 58 staffers in October 2017.
July 18, 2017 By Mark Terry, BioSpace.com Breaking News Staff Chicago, Ill. – Takeda Pharmaceuticals (TKPYY) is shifting hundreds of executives from the Chicago area to relocate to Boston. It is also cutting hundreds of field sales positions throughout the U.S. In March, the company indicated it was making job cuts in the Cambridge, […]